Patents Assigned to Protiva Biotherapeutics Inc.
-
Patent number: 8329070Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.Type: GrantFiled: December 10, 2010Date of Patent: December 11, 2012Assignee: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Lloyd Jeffs, Lorne R. Palmer, Cory Giesbrecht, Noelle Giesbrecht, legal representative
-
Patent number: 8283333Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.Type: GrantFiled: June 30, 2010Date of Patent: October 9, 2012Assignee: Protiva Biotherapeutics, Inc.Inventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
-
Patent number: 8236943Abstract: The present invention provides compositions and methods for the delivery of interfering RNAs that silence APOB expression to liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: GrantFiled: June 30, 2010Date of Patent: August 7, 2012Assignee: Protiva Biotherapeutics, Inc.Inventors: Amy C. H. Lee, Adam Judge, Marjorie Robbins, Ed Yaworski, Ian MacLachlan
-
Patent number: 8227443Abstract: The present invention provides compositions comprising nucleic acids that target CSN5 gene expression and methods of using such compositions to silence CSN5 gene expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence CSN5 gene expression and methods of use thereof, e.g., for treating cell proliferative disorders such as cancer. The present invention also provides nucleic acid-lipid particles that target CSN5 gene expression comprising an interfering RNA molecule, a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that inhibits aggregation of particles.Type: GrantFiled: October 13, 2010Date of Patent: July 24, 2012Assignees: Protiva Biotherapeutics, Inc., The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Ian MacLachlan, Adam Judge, Snorri S. Thorgeirsson, Yun-Han Lee
-
Publication number: 20120183581Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: ApplicationFiled: October 5, 2011Publication date: July 19, 2012Applicant: Protiva Biotherapeutics, IncInventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Publication number: 20120172411Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: ApplicationFiled: September 16, 2011Publication date: July 5, 2012Applicant: Protiva Biotherapeutics, Inc.Inventors: James Heyes, Mark Wood, Alan Martin
-
Patent number: 8188263Abstract: The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided.Type: GrantFiled: January 23, 2009Date of Patent: May 29, 2012Assignee: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Adam Judge, Amy C. H. Lee, Vandana Sood
-
Publication number: 20120058188Abstract: The present invention provides compositions and methods for silencing gene expression by delivering nucleic acid-lipid particles comprising a siRNA molecule to a cell.Type: ApplicationFiled: June 24, 2011Publication date: March 8, 2012Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Ellen Grace Ambegia, James Heyes
-
Patent number: 8101741Abstract: The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. The present invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided.Type: GrantFiled: November 2, 2006Date of Patent: January 24, 2012Assignee: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Adam Judge
-
Publication number: 20110313017Abstract: The present invention provides polyoxaline-dialkyloxypropyl conjugates (POZ-DAA), SNALP compositions comprising POZ-DAA conjugates and methods of using such SNALP compositions to introduce a therapeutic agent, such as a nucleic acid, into a cell (e.g., for the treatment of a disease or disorder).Type: ApplicationFiled: January 13, 2011Publication date: December 22, 2011Applicant: Protiva Biotherapeutics, Inc.Inventor: James Heyes
-
Patent number: 8058069Abstract: The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.Type: GrantFiled: April 15, 2009Date of Patent: November 15, 2011Assignee: Protiva Biotherapeutics, Inc.Inventors: Edward Yaworski, Kieu Lam, Lloyd Jeffs, Lorne Palmer, Ian MacLachlan
-
Publication number: 20110262527Abstract: The present invention provides compositions comprising cationic lipids, liposomes and nucleic acid-lipid particles comprising the cationic lipids, and methods of using such compositions, liposomes, and nucleic acid-lipid particles.Type: ApplicationFiled: June 8, 2010Publication date: October 27, 2011Applicant: Protiva Biotherapeutics, Inc.Inventors: James Heyes, Ian MacLachlan, Lorne R. Palmer
-
Publication number: 20110224418Abstract: The present invention provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains full RNAi activity against the target sequence. The present invention also provides nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided.Type: ApplicationFiled: February 14, 2011Publication date: September 15, 2011Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Adam Judge
-
Publication number: 20110216622Abstract: The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol.Type: ApplicationFiled: December 10, 2010Publication date: September 8, 2011Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Lloyd Jeffs, Lorne R. Palmer, Cory Giesbrecht, Noelle Giesbrecht
-
Publication number: 20110201667Abstract: The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.Type: ApplicationFiled: July 20, 2010Publication date: August 18, 2011Applicants: Protiva Biotherapeutics, Inc., Trustees of Boston University, United States Army Medical Research and Materiel CommandInventors: Thomas W. Geisbert, Amy C.H. Lee, Marjorie Robbins, Vandana Sood, Adam Judge, Lisa E. Hensley, Ian MacLachlan
-
Publication number: 20110195127Abstract: The present invention provides compositions and methods for the delivery of interfering RNAs that silence APOB expression to liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: ApplicationFiled: June 30, 2010Publication date: August 11, 2011Applicant: Protiva Biotherapeutics, Inc.Inventors: Amy C.H. Lee, Adam Judge, Marjorie Robbins, Ed Yaworski, Ian MacLachlan
-
Publication number: 20110189300Abstract: The present invention provides nucleic acid-lipid particles comprising siRNA molecules that silence ApoB expression and methods of using such nucleic acid-lipid particles to silence ApoB expression.Type: ApplicationFiled: May 20, 2010Publication date: August 4, 2011Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Lloyd B. Jeffs, Adam Judge, Amy C.H. Lee, Lorne R. Palmer, Vandana Sood
-
Publication number: 20110178155Abstract: The present invention provides compositions comprising nucleic acids that target CSN5 gene expression and methods of using such compositions to silence CSN5 gene expression. More particularly, the present invention provides unmodified and chemically modified interfering RNA molecules which silence CSN5 gene expression and methods of use thereof, e.g., for treating cell proliferative disorders such as cancer. The present invention also provides nucleic acid-lipid particles that target CSN5 gene expression comprising an interfering RNA molecule, a cationic lipid, a non-cationic lipid, and optionally a conjugated lipid that inhibits aggregation of particles.Type: ApplicationFiled: October 13, 2010Publication date: July 21, 2011Applicants: Protiva Biotherapeutics, Inc., The USA, as represented by the Secretary, Dept.of Health and Human ServicesInventors: Ian MacLachlan, Adam Judge, Snorri S. Thorgeirsson, Yun-Han Lee
-
Publication number: 20110177131Abstract: The present invention provides siRNA molecules that target Filovirus gene expression and methods of using such siRNA molecules to silence Filovirus gene expression. The present invention also provides nucleic acid-lipid particles that target Filovirus gene expression comprising an siRNA that silences Filovirus gene expression, a cationic lipid, and a non-cationic lipid.Type: ApplicationFiled: September 9, 2010Publication date: July 21, 2011Applicant: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Vandana Sood, Thomas W. Geisbert, Lisa E. Hensley, Elliott Kagan
-
Patent number: 7982027Abstract: The present invention provides compositions and methods for silencing gene expression by delivering nucleic acid-lipid particles comprising a siRNA molecule to a cell.Type: GrantFiled: June 27, 2006Date of Patent: July 19, 2011Assignee: Protiva Biotherapeutics, Inc.Inventors: Ian MacLachlan, Ellen Grace Ambegia, James Heyes